Stockreport

UroGen Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Developments

UroGen Pharma Ltd. - Ordinary Shares  (URGN) 
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.urogen.com
PDF Achieved Jelmyto® net product revenue of $8.0 million for the fourth quarter of 2020; $11.8 million in first seven months of commercialization Initiated ATLAS Phase III [Read more]